Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 8506072, 6 pages
https://doi.org/10.1155/2017/8506072
Research Article

Elevation of Platelet and Monocyte Activity Markers of Atherosclerosis in Haemodialysis Patients Compared to Peritoneal Dialysis Patients

11st Medical Department, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany
25th Medical Department, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany
3Herzzentrum Weinheim, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany

Correspondence should be addressed to Anna-Isabelle Kälsch; ed.mmu@hcsleak.ellebasi-annA

Received 24 January 2017; Revised 29 May 2017; Accepted 11 June 2017; Published 9 July 2017

Academic Editor: Giuseppe Valacchi

Copyright © 2017 Ksenija Stach et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Eknoyan, G. J. Beck, A. K. Cheung et al., “Effect of dialysis dose and membrane flux in maintenance hemodialysis,” The New England Journal of Medicine, vol. 347, no. 25, pp. 2010–2019, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Paniagua, D. Amato, E. Vonesh et al., “Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial,” Journal of the American Society of Nephrology, vol. 13, no. 5, pp. 1307–1320, 2002. View at Google Scholar
  3. A. Y. Wang, C. W. Lam, M. Wang et al., “Increased circulating inflammatory proteins predict a worse prognosis with valvular calcification in end-stage renal disease: a prospective cohort study,” American Journal of Nephrology, vol. 28, no. 4, pp. 647–653, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Sagripanti and G. Barsotti, “Bleeding and thrombosis in chronic uremia,” Nephron, vol. 75, no. 2, pp. 125–139, 1997. View at Publisher · View at Google Scholar
  5. E. P. Evans, R. A. Branch, and A. L. Bloom, “A clinical and experimental study of platelet function in chronic renal failure,” Journal of Clinical Pathology, vol. 25, no. 9, pp. 745–753, 1972. View at Publisher · View at Google Scholar
  6. M. Gawaz, F. J. Neumann, T. Dickfeld et al., “Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells,” Circulation, vol. 98, no. 12, pp. 1164–1171, 1998. View at Publisher · View at Google Scholar
  7. P. Boccardo, G. Remuzzi, and M. Galbusera, “Platelet dysfunction in renal failure,” Seminars in Thrombosis and Hemostasis, vol. 30, no. 5, pp. 579–589, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Libby, P. M. Ridker, and A. Maseri, “Inflammation and atherosclerosis,” Circulation, vol. 105, no. 9, pp. 1135–1143, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Gawaz, K. Brand, T. Dickfeld et al., “Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis,” Atherosclerosis, vol. 148, no. 1, pp. 75–85, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. P. S. Frenette, R. C. Johnson, R. O. Hynes, and D. D. Wagner, “Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 16, pp. 7450–7454, 1995. View at Google Scholar
  11. F. Locatelli, L. Del Vecchio, and C. Manzoni, “Morbidity and mortality on maintenance haemodialysis,” Nephron, vol. 80, no. 4, pp. 380–400, 1998. View at Publisher · View at Google Scholar
  12. A. E. May, T. Kälsch, S. Massberg, Y. Herouy, R. Schmidt, and M. Gawaz, “Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells,” Circulation, vol. 106, no. 16, pp. 2111–2117, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Mach, U. Schönbeck, G. K. Sukhova et al., “Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 5, pp. 1931–1936, 1997. View at Google Scholar
  14. N. Yorioka, Y. Taniguchi, K. Yamashita et al., “Tissue factor and tissue factor pathway inhibitor in hemodialysis patients,” The International Journal of Artificial Organs, vol. 21, no. 11, pp. 699–701, 1998. View at Google Scholar
  15. R. Pirzer, E. Elmas, D. Haghi et al., “Platelet and monocyte activity markers and mediators of inflammation in Takotsubo cardiomyopathy,” Heart and Vessels, vol. 27, no. 2, pp. 186–192, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. C. Chuang, J. B. Chen, L. C. Yang, and C. Y. Kuo, “Significance of platelet activation in vascular access survival of haemodialysis patients,” Nephrology, Dialysis, Transplantation, vol. 18, no. 5, pp. 947–954, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. J. T. Daugirdas and A. A. Bernardo, “Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia,” Kidney International, vol. 82, no. 2, pp. 147–157, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Malyszko, J. S. Malyszko, and M. Mysliwiec, “Comparison of hemostatic disturbances between patients on CAPD and patients on hemodialysis,” Peritoneal Dialysis International, vol. 21, no. 2, pp. 158–165, 2001. View at Google Scholar
  19. K. Pawlak, D. Pawlak, and M. Mysliwiec, “Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients,” Thrombosis Research, vol. 120, no. 6, pp. 871–6, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Pawlak, D. Pawlak, and M. Mysliwiec, “Association between tissue factor, its pathway inhibitor and oxidative stress in peritoneal dialysis patients,” Blood Coagulation & Fibrinolysis, vol. 18, no. 5, pp. 467–471, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. N. M. Al-Saady, E. W. Leatham, S. Gupta, J. T. Kwan, J. B. Eastwood, and C. A. Seymour, “Monocyte expression of tissue factor and adhesion molecules: the link with accelerated coronary artery disease in patients with chronic renal failure,” Heart, vol. 81, no. 2, pp. 134–140, 1999. View at Publisher · View at Google Scholar
  22. FHN Trial Group, G. M. Chertow, N. W. Levin et al., “In-center hemodialysis six times per week versus three times per week,” The New England Journal of Medicine, vol. 363, no. 24, pp. 2287–2300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. J. J. Scialla, L. C. Plantinga, W. H. Kao, B. Jaar, N. R. Powe, and R. S. Parekh, “Soluble P-selectin levels are associated with cardiovascular mortality and sudden cardiac death in male dialysis patients,” American Journal of Nephrology, vol. 33, no. 3, pp. 224–230, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Ashman, M. G. Macey, S. L. Fan, U. Azam, and M. M. Yaqoob, “Increased platelet-monocyte aggregates and cardiovascular disease in end-stage renal failure patients,” Nephrology, Dialysis, Transplantation, vol. 18, no. 10, pp. 2088–2096, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. V. Krane and C. Wanner, “At which stage of chronic kidney disease should dyslipidemia be treated?” Nature Clinical Practice. Nephrology, vol. 2, no. 4, pp. 176-177, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. B. C. Fellstrom, A. G. Jardine, R. E. Schmieder et al., “Rosuvastatin and cardiovascular events in patients undergoing hemodialysis,” The New England Journal of Medicine, vol. 360, no. 14, pp. 1395–1407, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Malyszko, J. S. Malyszko, T. Hryszko, and M. Mysliwiec, “Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients,” Blood Coagulation & Fibrinolysis, vol. 15, no. 6, pp. 463–467, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. R. F. Schwabe, H. Engelmann, S. Hess, and H. Fricke, “Soluble CD40 in the serum of healthy donors, patients with chronic renal failure, haemodialysis and chronic ambulatory peritoneal dialysis (CAPD) patients,” Clinical and Experimental Immunology, vol. 117, no. 1, pp. 153–158, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. W. Van Biesen, F. Verbeke, and R. Vanholder, “Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro peritoneal dialysis,” Nephrology, Dialysis, Transplantation, vol. 22, no. 1, pp. 53–58, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. S. K. Ganesh, T. Hulbert-Shearon, F. K. Port, K. Eagle, and A. G. Stack, “Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease,” Journal of the American Society of Nephrology, vol. 14, no. 2, pp. 415–424, 2003. View at Google Scholar
  31. A. G. Stack, D. A. Molony, N. S. Rahman, A. Dosekun, and B. Murthy, “Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States,” Kidney International, vol. 64, no. 3, pp. 1071–1079, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Sanabria, J. Muñoz, C. Trillos et al., “Dialysis outcomes in Colombia (DOC) study: a comparison of patient survival on peritoneal dialysis vs hemodialysis in Colombia,” Kidney International. Supplement, vol. 108, pp. S165–S172, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. F. C. Trespalacios, A. J. Taylor, L. Y. Agodoa, G. L. Bakris, and K. C. Abbott, “Heart failure as a cause for hospitalization in chronic dialysis patients,” American Journal of Kidney Diseases, vol. 41, no. 6, pp. 1267–1277, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Vanholder, G. Glorieux, N. Lameire, and European Uremic Toxin Work Group, “Uraemic toxins and cardiovascular disease,” Nephrology, Dialysis, Transplantation, vol. 18, no. 3, pp. 463–466, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Pecoits-Filho, O. Heimbürger, P. Bárány et al., “Associations between circulating inflammatory markers and residual renal function in CRF patients,” American Journal of Kidney Diseases, vol. 41, no. 6, pp. 1212–1218, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Remuzzi, M. Livio, G. Marchiaro, G. Mecca, and G. de Gaetano, “Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis,” Nephron, vol. 22, no. 4–6, pp. 347–353, 1978. View at Google Scholar
  37. E. M. Sloand, M. M. Bern, and A. Kaldany, “Effect on platelet function of hypoalbuminemia in peritoneal dialysis,” Thrombosis Research, vol. 44, no. 4, pp. 419–425, 1986. View at Publisher · View at Google Scholar · View at Scopus
  38. R. M. Lindsay, M. Friesen, F. Koens, A. L. Linton, D. Oreopoulos, and G. de Veber, “Platelet function in patients on long term peritoneal dialysis,” Clinical Nephrology, vol. 6, no. 2, pp. 335–339, 1976. View at Google Scholar
  39. F. Salvati and M. Liani, “Role of platelet surface receptor abnormalities in the bleeding and thrombotic diathesis of uremic patients on hemodialysis and peritoneal dialysis,” The International Journal of Artificial Organs, vol. 24, no. 3, pp. 131–135, 2001. View at Google Scholar